Moderna Inc MRNA shares are trading higher by 1.3% at $237.50 on continued strength after the company on Tuesday announced data showing its COVID-19 vaccine produced neutralizing titers against multiple COVID-19 variants.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020.
Moderna had 24 mRNA development programs as of early 2021, with 13 of these in clinical trials. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease and rare genetic diseases.
Moderna has a 52-week high of $245.70 and a 52-week low of $54.21.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
